Efficacy of Online Hemodiafiltrationlysis in Cytokine Removal
Primary Purpose
Sepsis, Acute Kidney Injury
Status
Completed
Phase
Not Applicable
Locations
Thailand
Study Type
Interventional
Intervention
On-line hemodiafiltration
High-flux Hemodialysis
Sponsored by
About this trial
This is an interventional treatment trial for Sepsis
Eligibility Criteria
Inclusion Criteria:
- Sepsis
- acute kidney injury (RIFLE classification F)
- Age more than 18
Exclusion Criteria:
- Hemodynamic instability
- Whom written informed consent could not be obtained
Sites / Locations
- King Chulalongkorn Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
On-line hemodiafiltration
High-flux hemodialysis (control)
Arm Description
On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
Outcomes
Primary Outcome Measures
Reduction in plasma Vascular Endothelial Growth Factor (VEGF)level
Secondary Outcome Measures
Intradialytic hypotension
Renal recovery (at 30 days)
Hospital patient mortality
mortality during hospital admission
Full Information
NCT ID
NCT01791712
First Posted
October 11, 2011
Last Updated
February 12, 2013
Sponsor
Chulalongkorn University
1. Study Identification
Unique Protocol Identification Number
NCT01791712
Brief Title
Efficacy of Online Hemodiafiltrationlysis in Cytokine Removal
Official Title
Enhanced Vascular Endothelial Growth Factor and Pro-inflammatory Cytokine Clearances With On-line Hemodiafiltration Versus High-flux Hemodialysis in Sepsis-related Acute Kidney Injury Patients
Study Type
Interventional
2. Study Status
Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
October 2011 (Actual)
Study Completion Date
October 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chulalongkorn University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Following the concept of "peak concentration hypothesis", which suggest the cutting peak of pro- and anti-inflammatory mediators would result in restoring a situation of immunohomeostasis. The investigators conducted the prospective randomized controlled trial aimed to compare the clearance efficacy between on-line hemodiafiltration and high-flux hemodialysis in sepsis-related acute kidney injury patients. The lowering cytokines level during sepsis is postulated to improved outcomes in sepsis.
Detailed Description
Blood samples were taken from patients before and at the end of 4-hour in the first dialysis session. The percentage of reductions were calculated from the before and ending samples. The values of postfilter samples were corrected for changes in plasma volume, based on hemoglobin (Hb) of prefilter.
VEGF and other cytokines (IL-6, IL-8, IL-10, and TNF-α) were determined in the plasma separated from EDTA blood. After collection, plasma separation was achieved by centrifugation for 10 min at 1,500 g. Immediately after separation, the samples were stored at -70 ºC until further analysis.
All determinations were carried out in duplicate. The panels of cytokines (VEGF, IL-6, IL-8, IL-10, and TNF-α) were measured using the Luminex xMap-based multiplex technology. Assays were performed using the MILLIPLEX MAP (multi-analyte panels) 5-plex Cytokine Kit (Millipore, Billerica, MA) on the Luminex® instrument according to the manufacturer's procedure.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Acute Kidney Injury
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
On-line hemodiafiltration
Arm Type
Experimental
Arm Description
On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
Arm Title
High-flux hemodialysis (control)
Arm Type
Active Comparator
Arm Description
The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
Intervention Type
Procedure
Intervention Name(s)
On-line hemodiafiltration
Other Intervention Name(s)
Nikkiso dialysis machine, ARROW dual lumen dialysis catheter, PureFlux -150H synthetic membrane dialyzer
Intervention Description
pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
Intervention Type
Procedure
Intervention Name(s)
High-flux Hemodialysis
Intervention Description
blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
Primary Outcome Measure Information:
Title
Reduction in plasma Vascular Endothelial Growth Factor (VEGF)level
Time Frame
At time 0-hour and 4-hour of the study dialysis session
Secondary Outcome Measure Information:
Title
Intradialytic hypotension
Time Frame
During 4 hours of the study dialysis session
Title
Renal recovery (at 30 days)
Time Frame
participants will be followed for the renal recovery (dialysis-free) for the 30 days from the first initiation of dialysis
Title
Hospital patient mortality
Description
mortality during hospital admission
Time Frame
participants will be followed for the duration of hospital stay (an expected average of 5 weeks)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Sepsis
acute kidney injury (RIFLE classification F)
Age more than 18
Exclusion Criteria:
Hemodynamic instability
Whom written informed consent could not be obtained
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Khajohn Tiranathanagul, M.D.
Organizational Affiliation
Chulalongkorn University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wiwat Chancharoenthana, M.D.
Organizational Affiliation
Chulalongkorn University
Official's Role
Principal Investigator
Facility Information:
Facility Name
King Chulalongkorn Memorial Hospital
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
12. IPD Sharing Statement
Learn more about this trial
Efficacy of Online Hemodiafiltrationlysis in Cytokine Removal
We'll reach out to this number within 24 hrs